Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

European Medicines Agency Recommends Granting a Marketing Authorisation for Sonidegib

Hedgehog pathway’s inhibitor, sonidegib, is intended for the treatment of locally advanced basal cell carcinoma
30 Jun 2015
Anticancer agents & Biologic therapy

On 25 June 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product sonidegib (Odomzo), intended for the treatment of adults with locally advanced basal cell carcinoma (BCC).

The applicant for this medicinal product is Novartis Europharm Ltd.

Odomzo will be available as 200 mg hard capsules. The active substance of Odomzo is sonidegib, an antineoplastic agent (ATC code:L01XX48). Sonidegib inhibits the Hedgehog pathway, a key regulator of development and morphogenesis in mammals, which is linked to the pathogenesis of several cancers including BCC.

The benefits with Odomzo are its ability to reduce locally advanced BCC lesions, with a response rate of about 54% and a progression-free survival of approximately 22 months.

The most common side effects of Odomzo treatment are muscle cramps, muscle pain, hair loss, alteration or loss of taste, nausea, diarrhoea, blood creatine phosphokinase increased weight decrease and fatigue. A pregnancy prevention plan and a pharmacovigilance plan for Odomzo will be implemented as part of the marketing authorisation.

The full indication is: "Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy."

It is proposed that Odomzo should only be prescribed by or under the supervision of a specialist physician experienced in the management of the approved indication.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 30 Jun 2015

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.